CCN1/CYR61 Cancer Research Results

CCN1/CYR61, Cellular Communication Network Factor 1 / Cysteine-Rich Angiogenic Inducer 61: Click to Expand ⟱
Source:
Type:

CCN1 - Cellular Communication Network Factor 1 / Cysteine-Rich Angiogenic Inducer 61

Abbreviation: CCN1, CYR61

Type: Matricellular protein / extracellular signaling protein

Function: CCN1 is a secreted extracellular-matrix-associated protein of the CCN family that regulates cell adhesion, migration, proliferation, survival, angiogenesis, inflammation, fibrosis, and cellular senescence. It interacts with several integrins and heparan sulfate proteoglycans, allowing it to produce different cellular responses depending on receptor and tissue context.

Cancer: ↕ Context-dependent, with a predominantly tumor-promoting pattern in many solid cancers. Increased CCN1/CYR61 can promote proliferation, survival, angiogenesis, migration, invasion, metastasis, cancer stem-like properties, tumor-microenvironment remodeling, and treatment resistance. However, CCN1 can also induce apoptosis or senescence through specific integrin-dependent pathways in some cellular contexts.
Scientific Papers found: Click to Expand⟱
7907- Api,  IVT,    Anticancer Potential of Apigenin and Isovitexin with Focus on Oncogenic Metabolism in Cancer Stem Cells
- Review, Var, NA
ChemoSen↑, Two natural flavonoids, apigenin and isovitexin, have been shown to act synergistically with conventional chemotherapeutic drugs by sensitizing CSCs, ultimately leading to improved therapeutic efficacy.
CSCs↓,
Wnt↓, suppression of the Wnt/β-catenin signaling pathway, the inhibition of nuclear factor-κB protein expression, and the downregulation of the cell cycle via upregulation of p21 and cyclin-dependent kinases
β-catenin/ZEB1↓,
PI3K↓, Figure 3
MMP↓,
TumMeta↓,
MAPK↓,
VEGF↓,
MMP9↓,
TGF-β↓,
Inflam↓,
COX2/PTGS2↓,
IL6↓,
NF-kB↓,
TumCCA↑,
P53↑,
cycD1/CCND1↓,
BAX↑,
Casp↓,
Bcl-2↓,
CD133↓, Brain U87MG and U373MG Apigenin 25–50 μM for 2–21 days ↓Self-renewal capacity, ↓cell growth, ↓clonogenicity, ↓invasiveness ↓CD133, ↓NANOG, ↓SOX2, ↓c-Met, ↓Akt
Nanog↓,
SOX2↓,
Akt↓,
TumCP↓, Breast MDA-MB-231 and MDA-MB-436 Apigenin 2–64 μM for 48 h ↓Proliferation, ↓migration, ↓stemness features, ↓mammospheres, ↓self-renewal capability ↓YAP/TAZ activity, ↓CTGF, ↓CYR61, ↓YAP/TAZ-TEADs
TumCMig↓,
YAP/TEAD↓,
CCN2/CTGF↓,
CCN1/CYR61↓,
SIRT3↓, Breast TNBCs Apigenin 12.5–200 µg/µL for 24 h ↓Stemness properties, ↓mammosphere formation, ↓clonogenic potential ↓SIRT3, ↓SIRT6
SIRT6↓,
PCNA↓, Osteosarcoma U2OS-SC tumors in nude mice Isovitexin 10–40 mg/kg for 2 weeks ↓Tumor growth, ↓tumor size ↓CD133, ↓PCNA, ↓Bcl-2, ↓ DNMT1, ↑apoptotic index, ↑miR-34a
DNMT1↓,
miR-34a↑,


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

CCN1/CYR61↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

SIRT3↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp↓, 1,   MAPK↓, 1,   YAP/TEAD↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNMT1↓, 1,   P53↑, 1,   PCNA↓, 1,   SIRT6↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD133↓, 1,   CSCs↓, 1,   miR-34a↑, 1,   Nanog↓, 1,   PI3K↓, 1,   SOX2↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

CCN2/CTGF↓, 1,   MMP9↓, 1,   TGF-β↓, 1,   TumCMig↓, 1,   TumCP↓, 1,   TumMeta↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL6↓, 1,   Inflam↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  
Total Targets: 36

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: CCN1/CYR61, Cellular Communication Network Factor 1 / Cysteine-Rich Angiogenic Inducer 61
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1719  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page